瑞格列奈和二甲双胍治疗继发性失效糖尿病的临床疗效比较研究

Comparative effectiveness research of repaglinide and metformin in treating secondary failure diabetes mellitus

目的比较瑞格列奈和二甲双胍治疗继发性失效糖尿病的临床疗效。方法选取徐州医科大学附属第三医院2014—2015年收治的继发性失效糖尿病患者114例,根据治疗方法的不同分为瑞格列奈组(n=57)和二甲双胍组(n=57)。瑞格列奈组患者给予瑞格列奈片治疗,二甲双胍组患者给予二甲双胍缓释片治疗,两组患者均以3个月为1个疗程。比较两组患者治疗前后空腹血糖、餐后2 h血糖及糖化血红蛋白水平,并统计患者不良反应发生情况。结果治疗前,两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白比较,差异无统计学意义(P>0.05);治疗后,瑞格列奈组患者空腹血糖、餐后2 h血糖及糖化血红蛋白水平低于二甲双胍组(P<0.05)。瑞格列奈组患者不良反应发生率低于二甲双胍组(P<0.05)。结论采用瑞格列奈治疗继发性失效糖尿病的临床疗效优于二甲双胍,其可更有效控制患者血糖,且安全性高。

Objective To compare the clinical effect of repaglinide and metformin in treating secondary failure diabetes mellitus. Methods A total of 114 cases of patients with secondary failure diabetes mellitus were selected from 2014 to 2015 years in the Third Affiliated Hospital Xuzhou Medical College,which were divided into repaglinide group（ n = 57） and metformin group（ n = 57） according to different treatments. Repaglinide group was treated with repaglinide,metformin group was treated with metformin,3 months as a course of treatment. The fasting blood glucose,2 h postprandial blood glucose,glycosylated hemoglobin were compared before and after treatment between the two groups,ans the incidence of adverse reactions were observed between the two groups. Results Before treatment,no statistically significant differences of fasting blood glucose,2 h postprandial blood glucose or glycosylated hemoglobin was found between the two groups（ P〉0. 05）; the repaglinide group of fasting blood glucose,2 h postprandial blood glucose,glycosylated hemoglobin were lower than metformin group（ P〈0. 05）. The incidence rae of adverse reactions of repaglinide group was significantly lower than metformin group（ P〈0. 05）. Conclusion Repaglinide has a higher clinical value in treating secondary failure diabetes mellitus than metformin,it can more effectively control the blood glucose,and with higher safety.